ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Tomotherapy Treatment for Mesothelioma

This study is currently recruiting participants.
Verified by Alberta Cancer Board, May 2007

Sponsored by: Alberta Cancer Board
Information provided by: Alberta Cancer Board
ClinicalTrials.gov Identifier: NCT00469196
  Purpose

Mesothelioma is an incurable cancer involving the lining of the lung. Patients usually suffer progressive symptoms of shortness of breath and chest pain, until they ultimately succumb to the disease. While a very small number of patients qualify for aggressive treatment with surgery, chemotherapy and radiation, and enjoy long-term survival, the vast majority of patients have incurable disease. The treatment options currently available, including chemotherapy and radiation treatment, are only modestly effective at alleviating symptoms and improving life expectancy. This trial explores the use of new radiation technology (tomotherapy), to treat mesothelioma more aggressively than has been possible before. Tomotherapy's ability to treat unusual shaped tumours, particularly when they are wrapped around sensitive normal tissues (the lung), enable higher doses of radiation to be used and this may improve its effectiveness. We will treat 17 patients with tomotherapy and assess the breathing, symptoms, and quality of life of the patients before and after treatment


Condition Intervention Phase
Mesothelioma
Procedure: Tomotherapy
Phase II

MedlinePlus related topics:   Cancer    Mesothelioma   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study
Official Title:   Tomotherapy Treatment for Mesothelioma

Further study details as provided by Alberta Cancer Board:

Estimated Enrollment:   17
Study Start Date:   October 2006

Show detailed description  Show Detailed Description

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • histologic mesothelioma
  • refused/ineligible for surgery or chemotherapy
  • life expectancy >3 months

Exclusion Criteria:

  • contraindications to thoracic radiotherapy
  • unable to lie flat for duration of radiation therapy
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00469196

Contacts
Contact: Rufus Scrimger, MD     780-432-8517     rufusscr@cancerboard.ab.ca    

Locations
Canada, Alberta
Cross Cancer Institute     Recruiting
      Edmonton, Alberta, Canada, T5N 2R8
      Contact: Deanna Gilbert, CCRP     780-432-8352     deannap@cancerboard.ab.ca    
      Principal Investigator: Rufus Scrimger, MD            

Sponsors and Collaborators
Alberta Cancer Board

Investigators
Principal Investigator:     Rufus Scrimger, MD     Alberta Cancer Board    
  More Information

Study ID Numbers:   LU-11-0077
First Received:   May 2, 2007
Last Updated:   May 2, 2007
ClinicalTrials.gov Identifier:   NCT00469196
Health Authority:   Canada: Health Canada

Keywords provided by Alberta Cancer Board:
mesothelioma  
tomotherapy  

Study placed in the following topic categories:
Mesothelioma
Adenoma
Neoplasms, Glandular and Epithelial

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Mesothelial

ClinicalTrials.gov processed this record on September 05, 2008




Links to all studies - primarily for crawlers